NCT06129175View on ClinicalTrials.gov

UCMSCs as Treatment for Patients With Acute Ischemic Stroke (Stroke Neuroncell-EX)

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 19, 2023

Primary Completion Date

February 8, 2025

Study Completion Date

May 31, 2025

Conditions
Acute Ischemic Stroke
Interventions
BIOLOGICAL

Neuroncell-EX

Intravenous infusion of Neuroncell-EX (2 million UCMSCs per kg body weight) on day 1 and day 14 plus standard medical care.

OTHER

Placebo

Intravenous infusion of Placebo (normal saline) on day 1 and day 14 plus standard medical care.

Trial Locations (1)

56000

RECRUITING

Hospital Canselor Tuanku Muhriz UKM, Cheras

All Listed Sponsors
collaborator

National University of Malaysia

OTHER

lead

Cytopeutics Sdn. Bhd.

INDUSTRY